Cargando…

Changing Therapy for Gastrinoma

Objective: The author analyzed potential survival determinants in gastrinoma to characterize a possible uniform staging system and to determine whether complete surgical resection improves expected survival. Summary and Background Data: Gastrinoma is an indolent yet malignant neuroendocrine tumor. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Bornman, P. C., Radebold, K.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 1998
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2423914/
https://www.ncbi.nlm.nih.gov/pubmed/9515242
http://dx.doi.org/10.1155/1998/62935
_version_ 1782156211644268544
author Bornman, P. C.
Radebold, K.
author_facet Bornman, P. C.
Radebold, K.
author_sort Bornman, P. C.
collection PubMed
description Objective: The author analyzed potential survival determinants in gastrinoma to characterize a possible uniform staging system and to determine whether complete surgical resection improves expected survival. Summary and Background Data: Gastrinoma is an indolent yet malignant neuroendocrine tumor. The associated gastric acid hypersecretion can be controlled medically. Staging of gastrinoma is inconsistent and the role Of surgical resection controversial. Methods: Seventy-four patients with gastrinoma with a minimum 5-year follow-up were assessed. Cox's proportional hazards regression model was used to examine the association of risk factors with survival. Results: The following factors had no effect on survival: age at diagnosis, sex, presence of lymph node metastases, associated multiple endocrine neoplasia, and method of ulcer treatment. The three unique determinants of survival were primary tumor size (relative risk 1.534; p<0.0005), liver metastases (relative risk, 2.947; p<0.0209), and complete surgical resection (relative risk 0.163; p<0.0076). On the basis of these risk factors, a uniform staging system is proposed and predictive survival curves developed. Conclusions: The primary determinants of survival in gastrinoma are the size of the primary tumor and liver metastases. Complete surgical resection reduces mortality, regardless of other factors.
format Text
id pubmed-2423914
institution National Center for Biotechnology Information
language English
publishDate 1998
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-24239142008-07-08 Changing Therapy for Gastrinoma Bornman, P. C. Radebold, K. HPB Surg Research Article Objective: The author analyzed potential survival determinants in gastrinoma to characterize a possible uniform staging system and to determine whether complete surgical resection improves expected survival. Summary and Background Data: Gastrinoma is an indolent yet malignant neuroendocrine tumor. The associated gastric acid hypersecretion can be controlled medically. Staging of gastrinoma is inconsistent and the role Of surgical resection controversial. Methods: Seventy-four patients with gastrinoma with a minimum 5-year follow-up were assessed. Cox's proportional hazards regression model was used to examine the association of risk factors with survival. Results: The following factors had no effect on survival: age at diagnosis, sex, presence of lymph node metastases, associated multiple endocrine neoplasia, and method of ulcer treatment. The three unique determinants of survival were primary tumor size (relative risk 1.534; p<0.0005), liver metastases (relative risk, 2.947; p<0.0209), and complete surgical resection (relative risk 0.163; p<0.0076). On the basis of these risk factors, a uniform staging system is proposed and predictive survival curves developed. Conclusions: The primary determinants of survival in gastrinoma are the size of the primary tumor and liver metastases. Complete surgical resection reduces mortality, regardless of other factors. Hindawi Publishing Corporation 1998 /pmc/articles/PMC2423914/ /pubmed/9515242 http://dx.doi.org/10.1155/1998/62935 Text en Copyright © 1998 Hindawi Publishing Corporation. http://creativecommons.org/licenses/by/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Bornman, P. C.
Radebold, K.
Changing Therapy for Gastrinoma
title Changing Therapy for Gastrinoma
title_full Changing Therapy for Gastrinoma
title_fullStr Changing Therapy for Gastrinoma
title_full_unstemmed Changing Therapy for Gastrinoma
title_short Changing Therapy for Gastrinoma
title_sort changing therapy for gastrinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2423914/
https://www.ncbi.nlm.nih.gov/pubmed/9515242
http://dx.doi.org/10.1155/1998/62935
work_keys_str_mv AT bornmanpc changingtherapyforgastrinoma
AT radeboldk changingtherapyforgastrinoma